ATNM Projected Dividend Yield
Actinium Pharmaceuticals Inc ( AMEX : ATNM )Actinium Pharmaceuticals is a clinical-stage biopharmaceutical company. Co.'s targeted radiotherapies combine the cell-killing ability of radiation via a radioisotope payload with a targeting agent to deliver radiation in a precise manner inside the body to specific targeted cells. Co.'s Iomab-B and Actimab-A product candidates are focused on addressing the medical needs in relapsed or refractory acute myeloid leukemia (AML) in a complementary manner and are directed at different parts of the patient journey. Iomab-B is a targeted radiotherapy consisting of apamistamab. Actimab-A (225Ac-lintuzumab satetraxetan) program is focused on developing combinations with other AML treatment regimens. 20 YEAR PERFORMANCE RESULTS |
ATNM Dividend History Detail ATNM Dividend News ATNM Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |